Candin is an approved diagnostic skin test and currently not approved by the FDA or Japan's Pharmaceuticals and Medical Devices Agency for the treatment of common warts. 

Vial is partnering with Nielsen BioSciences, Inc. to study the safety and efficacy of Candin for the treatment of common warts. 

Vial will support Nielsen with their Phase III, randomized, double-blind, placebo-controlled clinical study of Candin for the treatment of Verruca vulgaris in adolescents and adults in the U.S. and Japan. Phase III patient enrollment expected to start in the second half of 2023.

Candin is an approved diagnostic skin test and currently not approved by the FDA or Japan's Pharmaceuticals and Medical Devices Agency for the treatment of common warts. 

"Vial is thrilled to collaborate with Nielsen on their Phase III clinical trial in the U.S. and Japan. We are committed to delivering high-quality trials powered by innovative technology that are affordable for sponsors. We have full confidence in our ability to drive optimal outcomes for this important study," says Wendy Pinson, Senior Director of Clinical Operations at Vial, in a news release. Vial is a tech-enabled, next-generation Contract Research Organization (CRO).

"Common warts are estimated to affect 10 percent of the global population but have no prescription-approved treatment. We look forward to partnering with the Vial team on CANDIN's Phase III clinical trial," says David P. Burney, Ph.D., MBA, President and COO at Nielsen BioSciences. "Our thoughtful discussion with their team, combined with an outstanding comprehensive presentation, gave us full confidence that this important clinical trial for common warts will be managed to the highest standards in the industry."